생물제제 수탁제조 시장 : 제품별(바이오시밀러, 인슐린, 인터페론), 플랫폼별(포유류, 미생물), 치료 분야별 - 세계 예측(2023-2030년)

The Global Biologics Contract Manufacturing Market is forecasted to grow significantly, with a projected USD 22.82 billion in 2023 at a CAGR of 16.67% and expected to reach a staggering USD 67.44 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Biologics Contract Manufacturing Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Biologics Contract Manufacturing Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product, market is studied across Biosimilar, Insulin, Interferons, Monoclonal Antibodies, Recombinant Hormones, and Vaccines. The Insulin is projected to witness significant market share during forecast period.

Based on Platform, market is studied across Mammalian and Microbial. The Microbial is projected to witness significant market share during forecast period.

Based on Therapeutic Area, market is studied across Autoimmune Diseases, Cardiovascular Diseases, Infectious Diseases, Metabolic Diseases, Neurology, Oncology, Ophthalmology, and Respiratory Disorders. The Ophthalmology is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Biologics Contract Manufacturing Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Biologics Contract Manufacturing Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biologics Contract Manufacturing Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biologics Contract Manufacturing Market?

4. What is the competitive strategic window for opportunities in the Global Biologics Contract Manufacturing Market?

5. What are the technology trends and regulatory frameworks in the Global Biologics Contract Manufacturing Market?

6. What is the market share of the leading vendors in the Global Biologics Contract Manufacturing Market?

7. What modes and strategic moves are considered suitable for entering the Global Biologics Contract Manufacturing Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Biologics Contract Manufacturing Market, by Product, 2022 vs 2030
• 4.3. Biologics Contract Manufacturing Market, by Platform, 2022 vs 2030
• 4.4. Biologics Contract Manufacturing Market, by Therapeutic Area, 2022 vs 2030
• 4.5. Biologics Contract Manufacturing Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing demand for biosimilars and vaccine production
    • 5.1.1.2. Ongoing investment activities by CMOs for capacity expansion
    • 5.1.1.3. Key advantages such as cost and time saving offered by contract services
  • 5.1.2. Restraints
    • 5.1.2.1. Changing trade policies between countries
  • 5.1.3. Opportunities
    • 5.1.3.1. Emergence of single-use bioprocessing equipment & solutions
    • 5.1.3.2. Rising demand for cell and gene therapies for targeted treatment
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns over the breach of intellectual property and patents
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Biologics Contract Manufacturing Market, by Product

• 6.1. Introduction
• 6.2. Biosimilar
• 6.3. Insulin
• 6.4. Interferons
• 6.5. Monoclonal Antibodies
• 6.6. Recombinant Hormones
• 6.7. Vaccines

7. Biologics Contract Manufacturing Market, by Platform

• 7.1. Introduction
• 7.2. Mammalian
• 7.3. Microbial

8. Biologics Contract Manufacturing Market, by Therapeutic Area

• 8.1. Introduction
• 8.2. Autoimmune Diseases
• 8.3. Cardiovascular Diseases
• 8.4. Infectious Diseases
• 8.5. Metabolic Diseases
• 8.6. Neurology
• 8.7. Oncology
• 8.8. Ophthalmology
• 8.9. Respiratory Disorders

9. Americas Biologics Contract Manufacturing Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Biologics Contract Manufacturing Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Biologics Contract Manufacturing Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. FPNV Positioning Matrix
• 12.2. Market Share Analysis, By Key Player
• 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

• 14.1. Discussion Guide
• 14.2. License & Pricing